May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Pegaptanib Sodium (Macugen®) as an Adjunct in the Management of Refractory Proliferative Diabetic Retinopathy and Clinically Significant Macular Edema
Author Affiliations & Notes
  • Y.-T. J. Su
    Retina, Valley Retina Institute, P.A., McAllen, Texas
  • V. H. Gonzalez
    Retina, Valley Retina Institute, P.A., McAllen, Texas
  • V. R. Vann
    Retina, Valley Retina Institute, P.A., McAllen, Texas
  • R. M. Banda
    Retina, Valley Retina Institute, P.A., McAllen, Texas
  • G. P. Giuliari
    Retina, Valley Retina Institute, P.A., McAllen, Texas
  • D. A. Guel
    Retina, Valley Retina Institute, P.A., McAllen, Texas
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1420. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y.-T. J. Su, V. H. Gonzalez, V. R. Vann, R. M. Banda, G. P. Giuliari, D. A. Guel; Pegaptanib Sodium (Macugen®) as an Adjunct in the Management of Refractory Proliferative Diabetic Retinopathy and Clinically Significant Macular Edema. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1420.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To assess the safety and efficacy of intravitreal injection of pegaptanib sodium (Macugen) for the management of proliferative diabetic retinopathy (PDR) and clinically significant macular edema (CSME), not responding to standard of treatment modalities.

Methods:: Retrospective chart review of 10 eyes from 10 patients from a private clinical setting. An intravitreal injection of 0.3 mg pegaptanib sodium was administered to each eye. Assessments were performed with Snellen visual acuity testing, slit lamp biomicroscopy, fundus exam, fluorescein angiography and optical coherence tomography (OCT).

Results:: Marked regression of neovascularization associated with PDR was noted in 90% of the eyes after intravitreal administration of pegaptanib. Additionally, foveal thickness was found to have improved appreciably. Stabilization in visual acuity was associated with these anatomical changes. No systemic complications have been identified through 6 months of follow up.

Conclusions:: These data demonstrate the tolerability and efficacy of intravitreal pegaptanib sodium as an adjunct in the treatment of PDR and CSME. Most notable is the marked regression of NVD and/or NVE in patients with PDR in addition to the decreasing anatomic extent of the concomitant CSME. Our findings suggest that selective VEGF blockade may allow for less laser therapy (with avoidance of its destructive side effects and induced macular edema) in treating diabetic retinopathy. Intravitreal pegaptanib sodium may reduce the progression of PDR and provide beneficial effects in preventing severe vision loss in patients not responding to standard therapy. Selective VEGF blockade may augment our practice patterns in treating diabetic retinopathy.

Keywords: diabetes • diabetic retinopathy • retinal neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×